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Strengths and limitations of this study
 Ź To our knowledge, this is the irst study to explore in 
depth the experiences and infant feeding behaviours 
of women using intravenous remifentanil patient- 
controlled analgesia (PCA) for pain relief in labour.
 Ź Substantial number of women (49) interviewed from 
multiple sites across England.
 Ź Fewer women recruited who had used pethidine 
(19) compared to remifentanil PCA (30).
 Ź A high number of women also received Entonox pri-
or to randomisation and in combination with peth-
idine (41; 84%), and some progressed to epidural 
analgesia (11; 22%) which may have inluenced 
their experiences.
AbStrACt
Objectives To explore women’s experiences of 
remifentanil or pethidine for labour pain and infant feeding 
behaviours at 6weeks post partum.
Design Qualitative postnatal sub- study to the randomised 
controlled trial of remifentanil intravenous patient 
controlled analgesia (PCA) versus intramuscular pethidine 
for pain relief in labour (RESPITE). Semistructured 
telephone interviews were conducted at 6 weeks post 
partum, and thematic analysis was undertaken.
Setting Women recruited to the RESPITE trial from seven 
UK hospitals.
Participants Eighty women consented and 49 (30 
remifentanil group and 19 pethidine group) completed the 
interview.
results Eight themes emerged which encompassed 
women’s antenatal plans for pain management (Birth 
Expectations) through to their future preferences for 
pain relief (Relections for Future Choices). Many women 
who used remifentanil felt it provided effective pain 
relief (Effectiveness of Pain Relief), whereas women in 
the pethidine group expressed more mixed views. Both 
groups described side effects, with women using pethidine 
frequently reporting nausea (Negative Physiological 
Responses) and women using remifentanil describing 
more cognitive effects (Cognitive Effects). Some women 
who used remifentanil reported restricted movements due 
to technical aspects of drug administration and fear of 
analgesia running out (Issues with Drug Administration). 
Women described how remifentanil enabled them to 
maintain their ability to stay focused during the birth 
(Enabling a Sense of Control). There was little difference in 
reported breastfeeding initiation and continuation between 
pethidine and remifentanil groups (Impact on Infant 
Behaviour and Breastfeeding).
Conclusions Qualitative insights from a follow- up study 
to a trial which explored experiences of intravenous 
remifentanil PCA with intramuscular pethidine injection 
found that remifentanil appeared to provide effective pain 
relief while allowing women to remain alert and focused 
during labour, although as with pethidine, some side 
effects were noted. Overall, there was little difference in 
reported breastfeeding initiation and duration between the 
two groups.
trial registration number ISRCTN29654603.
IntrODuCtIOn
Women's experiences of and response to 
pain during labour are complex, affected 
by multiple physiological and psychosocial 
factors, and consequently many women in 
labour require some form of pain relief.1 In 
line with the rise in the use of technology and 
intervention in childbirth, pharmacological 
pain management is widely offered to women 
in labour on maternity/obstetric units. Tradi-
tional pharmacological approaches for pain 
management include opioid analgesics, 
epidural analgesia and inhaled analgesia 
(Entonox): 50:50 oxygen and nitrous oxide). 
Epidural analgesia has been shown to be the 
most effective form of pain relief for labour 
but may give rise to unwanted side effects. 
Systematic reviews of trials have identified 
that epidural analgesics increase the duration 
of second stage labour and the risk of instru-
mental vaginal delivery.2
It has been reported that up to 25% of 
women in the UK use pethidine or a similar 
opioid during labour.3 While pethidine is 
known to alleviate labour pain for some 
women, when compared with placebo no clear 
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differences have been observed in maternal satisfaction 
with pain relief or the number of women requesting an 
epidural analgesic.4 Pethidine is known to cause maternal 
side effects, including nausea, vomiting and sedation.1 
Opioids readily cross the placenta, and neonatal respi-
ratory depression and hypothermia remain concerns.1 
Intrapartum pethidine administration may have a detri-
mental effect on neonatal behaviour, reducing infant 
alertness, suppressing the rooting and sucking reflex, and 
may shorten breastfeeding duration.5
There is increasing interest in the role of remifentanil 
as an alternative opioid analgesia in labour.6 Remifent-
anil is a potent opioid medication with a short half- life, 
administered by patient- controlled analgesia (PCA), 
allowing the woman to have the drug as and when it is 
needed, on demand. A systematic review conducted in 
2012, based on a few low- quality small trials comparing 
remifentanil to pethidine administered by various 
routes, reported a reduction in progression to epidural 
analgesia with remifentanil.7 A recent Cochrane review, 
again including only small poor- quality trials, compared 
PCA remifentanil to alternative parenteral methods of 
pain relief in labour, and found that remifentanil (PCA) 
provided more effective pain relief, and women were 
more satisfied with pain relief compared to other opioids 
administered intravenously, intramuscularly or using 
PCA.8 Known side effects of remifentanil include respi-
ratory depression, nausea, pruritus, and decreased heart 
rate and blood pressure, although there are currently 
too few studies of remifentanil PCA use in labour to draw 
definite conclusion with respect to side effects for women 
and newborns.8 Route of analgesia administration has 
been found to positively impact on women’s experiences 
of labour, with women who self- administered analgesia 
(intranasal fentanyl) reporting increased autonomy 
and satisfaction compared to women who relied on the 
midwife to administer analgesia, who were more often 
focused on the physical effect of the drug.9 The influence 
of remifentanil on infant feeding behaviours remains 
largely unexplored.
In this paper, we report on a qualitative follow- up sub- 
study to an open- label randomised controlled trial under-
taken in 14 UK maternity units. The main aim of the trial 
(RESPITE) was to compare intravenous remifentanil 
PCA with intramuscular pethidine injection to deter-
mine whether remifentanil PCA reduced progression to 
epidural analgesia; also to consider whether it resulted 
in any adverse maternal or neonatal sequelae. The trial 
found that remifentanil intravenous PCA halved epidural 
analgesia conversion rate, compared with intramuscular 
pethidine.10 The importance of combining qualitative 
evidence that explores the views and experiences of service 
users alongside quantitative evidence to inform safety, 
effectiveness and cost of interventions to inform ante-
natal and intrapartum guidelines has been recognised by 
the WHO.11 12 The focus of this follow- up sub- study was to 
explore women’s birth experiences, perceptions of their 
pain relief and infant feeding behaviours up to 6 weeks 
post partum, in women allocated to the pethidine or 
remifentanil trial arms for labour pain.
MethODOlOgy
Design
Full details of the RESPITE trial are reported elsewhere.10 
This sub- study follow- up phase was an adjunct to the trial, 
and comprised a qualitative exploratory study using semi-
structured telephone interviews.
Participants gave written informed consent before 
taking part.
recruitment
Fourteen UK obstetric- led maternity units took part in 
the RESPITE trial, where all women booked for delivery 
at participating centres were informed about the study at 
their antenatal visits. Women were eligible for the trial 
if they met the following inclusion criteria: 16 years or 
older and beyond 37 weeks’ gestation, with a singleton 
live baby, in cephalic presentation, who were in estab-
lished labour (defined as regular painful contractions 
irrespective of cervical dilatation), intending vaginal 
birth and were not participating in any other drug trial. 
For the qualitative sub- study, women who participated in 
the trial were approached by a research midwife/nurse 
after childbirth, while an inpatient, and provided with a 
separate information leaflet. Women who were willing to 
take part in a telephone interview up to approximately 
6 weeks post- partum were asked to sign a consent form. 
Participant contact details for consenting women were 
securely transferred to the research team, with all identi-
fiable data stored on encrypted university files.
Verbal consent was reconfirmed at the time of inter-
view. Women were recruited over a 16 month period 
(between June 2015 and September 2016), and maternity 
units that recruited the most women within a 1- month 
period received a £100 Love to Shop voucher.
Interviews
Semistructured audio- recorded telephone interviews 
were conducted between 5 and 8 weeks post partum by 
two researchers (JC, HS). Telephone interviews provided 
participants with the opportunity to disclose intimate 
and sensitive experiences without feeling uncomfortable. 
The interviews lasted between 20–30 min and explored 
women’s prebirth expectations for pain relief, their expe-
riences and perceived impact of pain- relief on maternal or 
infant behaviours, and infant feeding. Questions such as 
‘How did the pain relief affect your labour? (eg, emotion-
ally, physically)’, ‘How did you feel after the birth?’ and 
‘How was your baby following the birth?’ were posed. All 
women who took part in an interview received a £10 Love 
to Shop voucher to thank them for their participation.
Analysis
All interviews were transcribed verbatim, anonymised 
and uploaded into NVIVO qualitative software.13 Data 
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Table 1 Demographic information of study participants
Remifentanil 
(n=30)
Pethidine 
(n=19) Total (n=49)
Age of women (years)
  Mean (SD) 29.3 (5.2) 25.9 (4.5) 28.0 (5.2)
  Range 19–39 17–34 17–39
Ethnicity
  White 23 14 37
  Asian (Indian) 2 1 3
  Asian (Pakistani) 2 4 6
  Mixed 1 0 1
  Other 2 0 2
Marital status       
  Married/living with 
partner
30 17 47
  Single 0 2 2
Parity       
  Nulliparous 21 13 34
  Parous 9 6 15
Type of birth       
  Vaginal 26 15 41
  Caesarean 4 4 8
Additional pain relief administered   
  Epidural analgesia 4 7 11
  Pethidine 4 4 8
  Entonox 24 17 41
Infant feeding intention   
  Breast feeding 21 12 33
  Formula feeding 6 6 12
  No prebirth plans 3 1 4
Infant feeding initiation within the irst hour postbirth
  Breast feeding 14 8 22
  Formula feeding 16 11 27
Infant feeding status at ~6 weeks
  Exclusive breast 
feeding
7 0 7
  Formula feeding 16 14 30
  Mixed feeding 7 5 12
collection and analysis was undertaken concurrently, 
and Braun and Clark’s thematic approach14 was under-
taken to identify patterned meaning across the dataset. 
Two authors (JC, HS) undertook this work (under the 
guidance of VHM and GT) through an iterative process 
of reading, identifying key codes, grouping codes into 
sub- themes and finally creating themes that were reflec-
tive of all views expressed. We paid particular attention 
to how women’s experiences of pethidine and remifent-
anil, within the context of the trial, compared or differed. 
Analytical decisions were discussed and shared with all 
authors both periodically and at the end, to agree on final 
themes.
Patient and public involvement
Members of the Public and Researchers Involvement 
in Maternity and Early pregnancy group, a group of 
maternity service users convened by the University of 
Birmingham, were involved in reviewing the participant 
information during study set- up and were represented on 
the Trial Steering Committee for the RESPITE trial.
reSultS
Eighty trial participants from seven hospitals agreed to 
take part in the RESPITE postnatal sub- study. While all 14 
sites participating in the RESPITE trial were eligible for 
the sub- study, only seven hospitals successfully consented 
participants who progressed to interview. Four mater-
nity units received £100 in shopping vouchers as reward 
for recruiting the most women within a 1 month period. 
Despite numerous contact attempts, 23 women were not 
interviewed due to women being unavailable during the 
timeframe of the study or due to language barriers. Eight 
women asked to be withdrawn from the study prior to 
interview. Forty- nine participants (30 remifentanil and 19 
pethidine) took part in a telephone interview and were 
included for analysis.
Demographic information of participants is provided 
in table 1. Eight women received pethidine before they 
entered the trial (trial eligibility stipulated no systemic 
opioid pain relief within the previous 4 hours), four of 
whom were subsequently assigned to the pethidine trial 
arm, and four to the remifentanil arm. The majority of 
women (41/49) received gas and air (Entonox) pain 
relief in addition to the trial drug. Overall, 11 women 
progressed to epidural analgesia: seven from the peth-
idine arm (conversion rate of 64%) and four from the 
remifentanil arm (conversion rate of 36%), somewhat 
higher than the conversion rates seen in the main trial 
(41% and 19% for pethidine and remifentanil respec-
tively).10 Of the 11 women who had an epidural analgesic, 
five women had a caesarean section; two from the pethi-
dine arm and three from the remifentanil arm. A further 
three women had a caesarean section without having had 
epidural analgesia.
In the following section, we report on eight inter-
linking themes, relating to women’s expectations and 
experiences of pain relief, and the impact of analgesia 
on women’s experiences of infant feeding across the 
cohort; with similarities and differences in the experi-
ences of different forms of pain relief highlighted. As 
no stark differences were found between the responses 
of nulliparous and parous women, no differentiation was 
made in the findings. A selection of participant quotes 
are included, together with an identifier that reports that 
participant number, and either an R (remifentanil) or P 
(pethidine) suffix to indicate their group allocation.
The eight themes identified encompass women’s plans 
for pain management in the antenatal period (Birth Expec-
tations), through to how their experiences of using either 
remifentanil or pethidine may influence their future 
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preferences for pain relief in labour (Reflections for Future 
Choices). Four themes centred around women’s physio-
logical and cognitive responses to the analgesics (Nega-
tive Physiological Response; Cognitive Effects), and reflections 
on how effective pethidine and remifentanil were for 
pain relief (Effectiveness of Pain Relief) or pain manage-
ment (Enabling a Sense of Control). Additional themes 
highlighted common issues with the administration of 
the analgesics which may have impacted negatively on 
women’s experiences (Issues with Drug Administration), 
and their reflections on whether they felt the analgesics 
had an influence on their newborns and the establish-
ment of breast feeding (Impact on Infant Behaviour and 
Breastfeeding).
birth expectations
There were wide variations in women’s approaches to 
birth planning. These ranged from some women having 
no clear plans; ‘there wasn’t any plans, no’ (14R) or how 
women ‘just went with the flow’ (36R), to having very 
specific intentions; ‘Yes I did a lot of planning, I knew 
exactly what I wanted’ (50R). Often women’s approaches 
to labour were related to their previous childbirth expe-
riences. Prior experiences of unfulfilled birth plans often 
led women to adopt a more flexible perspective due to 
the uncertainty of childbirth:
Last time I was determined I wasn’t going to have an 
epidural and then things didn’t quite go according 
to plan so I had an epidural, so this time I decided to 
be, you know to go more with an open mind, because 
things can’t be planned as much as you would like. 
(36R)
The lack of a specific birth plan did not mean that 
women held no preferences or opinions regarding pain 
relief. Many women had actively researched pain relief 
options in a variety of ways, such as through antenatal 
classes, internet searches, and discussions with friends and 
family, although only two women had any prior knowl-
edge of remifentanil. Some women considered pethidine 
to be the best available option:
Well I’d looked at all the different types of pain relief 
beforehand and decided it was the one that I thought 
would be the best, so the pethidine. (15P)
However, others were less inclined to use pethidine due 
to the potential impact on the baby:
It was really just the fact that it [pethidine] crossed 
over [to] the baby, and like I didn’t really want him 
coming out sleepy. (55P)
Almost all the women interviewed were initially opposed 
to having an epidural analgesic due to reasons such as 
needle phobia, prior negative experience of epidural 
analgesia and vicarious reports of risk:
I’d heard so many stories of people having nerve 
damage and complications. (16P)
For a few of the women, their reticence reflected cultural 
expectations of how childbirth should be managed:
I think it’s a culture thing. Like, originally my parents 
are from [country], they’re very against it [epidural]. 
I don’t know if it’s a myth or if there’s any, or there 
is any research to back it up but they say it can cause 
lots of problems in the future and stuff like that. So 
we’ve kind of just been brought up around that. I’ve 
always kind of been told, ‘Oh yeah, you know don’t 
get that’. (33P)
negative physiological responses
Women from both trial arms reported what they consid-
ered to be side effects and negative impacts of the anal-
gesia on their physiological responses. While pethidine 
has a well- known sedative effect, for some of the women 
in our study this was not related to effective pain relief, 
and rather became problematic when it rendered them 
incapable of staying awake in labour:
Well I just remember them giving me an injection 
and […] it just made me, literally just trying not to 
fall asleep, that’s how it felt. Like my eyes were really 
heavy and I were just nodding off but I was still in 
so much pain it just made things a bit worse if I’m 
honest because it didn’t feel like it was numbing the 
pain at all it just literally made me want to go to sleep 
and I couldn’t. […] … (73P – progressed to epidural 
analgesia)
Some women across both trial arms experienced drows-
iness to the point that it interfered with their autonomy 
and mobility during labour:
I was lying down and they told me not to move too 
much because obviously because it makes you that 
drowsy and that sleepy that it’s best to stay in one po-
sition and just to press a button when you feel the 
pain. (45R)
Many of the women in the trial already had their 
mobility restricted by monitors, oxytocin infusion 
and so on, and some of these women found that the 
delivery of remifentanil through a PCA device requiring 
continuous intravenous access further restricted their 
mobility:
I found it [labour] very painful and I couldn’t walk 
around, I couldn’t really be on all fours very easily. 
All the things that I had imagined, I just couldn’t do 
because I was attached to the machine as well so yeah 
[…] (65R)
Several women in the pethidine arm reported experi-
encing vomiting or nausea, compared to only one woman 
in the remifentanil group. However, this woman reflected 
that it was difficult to disentangle the effects of remifent-
anil from the side effects of other analgesia:
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Perhaps a little bit drowsy because I know I was a bit 
in and out, and I was quite sick but I don’t know if 
that was gas and air more than the actual drug. (74R)
Furthermore, for some women, their adverse physio-
logical responses to remifentanil were only experienced 
when the analgesia ‘ran out’:
The only thing I would say is because I was on it for 
quite a long time, the drip actually ran out and when 
the drip ran out, I had quite bad sickness and like 
body- shaking, my whole body was shaking, also it kind 
of, I think it got blocked at one point as well so that 
happened twice where like I was violently throwing 
up everywhere. (60R)
On some occasions, as reflected in the following quote, 
symptoms associated with remifentanil led some women 
to cease using this form of pain relief:
…the first couple of times I did it okay, from the first 
go I didn’t, I said I don’t feel right and then after 
that I couldn’t focus enough to even press the button 
when I needed to… I was just not with it, and then 
my hubby said, ‘Oh can I press it for you?’, but the 
midwife said, ‘Oh no it’s got to be…’, it had to be 
me that did it. But I just couldn’t, so I think in total I 
only pressed it probably four or five times and then 
decided to stop because I just didn’t, I just didn’t like 
it at all. (36R)
effectiveness of pain relief
There were mixed views regarding the effectiveness of 
pethidine for pain relief. Some women were happy with 
the pain relief obtained from pethidine; ‘it was brilliant. 
I literally didn’t feel a thing until after she was born’ 
(38P). Women were satisfied with its effectiveness, partic-
ularly when used in combination with other pain- relief 
methods, for example, gas and air:
When I just had the gas and air it just felt like, wasn’t 
really working at all, wasn’t really doing anything but 
then obviously the two together just sort of took the 
edge off a little bit. Obviously I remember still feeling 
a bit of pain but it’s sort of bearable if you like, a bit 
more bearable. Yeah, definitely felt the difference. 
(52P)
From a counter- perspective, half of the women who 
received pethidine reported that their pain relief had 
been ineffective. These women reported about how they 
could ‘feel everything’ and how it had made ‘no differ-
ence’ to the intensity of their contractions:
I didn’t find the pethidine any help. It didn’t help me 
at all […] like, she said that it would like ease the con-
tractions off, you know like the pain, but I didn’t feel, 
I could still feel the pain when she, after the pethi-
dine got injected in I could still feel everything […] It 
might help other women but it didn’t help me. (79P)
In contrast, only a few women found remifentanil inef-
fective as pain relief. However, this minority of accounts 
were generally related to delivery of the medication or its 
inability to prevent pain caused by the baby’s position in 
utero:
As the labour progressed, because my son was back- 
to- back, a lot of the pain was in my back and I found 
it helped with the contractions but not necessarily the 
back pain in between the contractions. (58R)
Overall, there was a notable enthusiasm for remifent-
anil among participants. Some women described experi-
encing ‘no pain’ after its administration, whereas others 
referred to how it made the pain more bearable:
Yes, it did. It definitely did help because before that 
it was just getting really unbearable. It was just so un-
bearable, I just couldn’t, I felt as if I wanted to die 
[laughs], I know that’s an exaggeration but that’s 
how it feels at that point where you just can’t bear 
that pain but when I took that medication or pain 
relief, it took that pain away. Obviously as soon as I 
felt that contraction coming, press the buzzer and it’s 
like more than half of it were gone and it were just, it 
just slowly eases it all off and it were quite good. It was 
bearable then. (59R)
enabling a sense of control
One of the key benefits of remifentanil highlighted by 
women was how it provided pain relief and maintained 
their ability to stay alert, awake or focused during the 
birth:
I still remember being very alert and having to listen 
to what the midwives were saying, you know push and 
everything, so I was still very alert and able to do what 
I needed to do […] (44R)
For some women, being connected to a cannula did not 
substantially restrict their ability to move from the bed 
during labour, which, as reflected in the quote below, 
could have a positive impact on women’s agency and 
self- efficacy:
That’s what I wanted to do anyway. I wanted a water 
birth. I wanted to be active. As soon as I got into la-
bour anyway, before I had that medication, I didn’t 
want to be on the bed, I hated being on the bed, be-
ing stuck with, restricted. I didn’t like it, I just wanted 
to be able to move and it started giving me a little bit 
more confidence as well, you know, I just, not even, 
obviously I didn’t care, I just wanted to get her out. 
I couldn’t have done it without that [remifentanil], I 
really couldn’t. (50R)
Women often needed time and practice to get into 
the rhythm of delivering remifentanil via the PCA. Once 
mastered, several women talked about how the PCA 
enabled them to retain a sense of control by actively 
managing their own labour:
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But it was just so nice that you could be in control 
of it and it was one of those things that I didn’t have 
to have it all the time. So, for example, with contrac-
tions, I’d press the button on the first, you know, with 
one contraction, and then I wouldn’t have it for a 
couple of times because I’d be in control of my body, 
if that makes sense. […] And for me, it was just what 
I wanted, I could feel, I was in control of me, I was in 
control of my body. I knew what was going on in my 
surroundings. (1R)
This capacity for self- regulation was supported by the 
immediate impact of remifentanil on women’s physiolog-
ical responses:
But I noticed as well, when I pressed the buzzer, it 
worked straightaway, you know, the pain… […] I just 
noticed like when I pressed the buzzer, you know, 
when I pressed the buzzer, you know, for pain relief, 
it was like instant, yes, the pain just like went. (12R)
The ability to maintain focus was strongly linked to the 
short- acting effect of remifentanil. The fact that each 
dose of remifentanil wore off quickly was experienced as 
empowering. One participant found that discontinuing 
use of the PCA quickly re- established the control she felt 
she was lacking:
I really feel like when it came to the time of needing 
to push and things, when you’re having to do sort of 
certain things at certain times, I needed to, I would 
have struggled if I had still been taking it because I 
couldn’t kind of concentrate on anything, whereas 
because I’d stopped it and it was pretty much out of 
my system I was able to focus more. So I don’t think it 
was in my system for very long. (36R)
On occasion, these positive effects were contrasted with 
women’s previous experience of using pethidine:
It was, obviously, because you’ve got control of it. So, 
you know, you were able to press it when you needed 
it. Whereas like, if you have the pethidine and that, 
once you’ve been given it you’ve got no control over 
how it’s going to work. (14R)
While some of the women who had received pethidine 
made positive comments about its impact on their sense 
of control during labour, this was often in the context of 
providing respite to manage their labour pains:
So I had the pain relief for a good few hours which 
had kind of given me a bit of respite actually because 
I was getting quite tired and quite, I really needed 
pain relief so when I got that then it just gave me a 
little bit of respite…(6R)
Cognitive effects
Some women, particularly in the remifentanil group, 
reported cognitive effects consistent with systemic opioids. 
For some, this was a negative experience, associated with 
a sense of vulnerability, where they felt unable to focus 
or process external stimuli and could, as reflected below, 
negate the potential salutary effects of medication use on 
labour pains:
I was, I don’t really know the technical term, almost 
knocked out by it, it made me really sort of, I don’t 
know if that’s the right word but I was really out of 
it, I couldn’t focus, it was almost […] like it was too 
strong for me and they reduced the dose of it but 
[…] the midwife was trying to ask me questions and 
give me instructions as they do, it’s ongoing, and I 
really couldn’t […] focus because I was almost sort of 
not in the room as it were, so for me that sort of, sort 
of negated any positive effect it would have had on 
the pain relief side of things. (36R)
Whereas while other women described feeling ‘out of 
it’ or ‘away with the fairies’ after remifentanil administra-
tion, this was not always seen as being entirely negative:
I would say it did take away my control and my sort 
of presence in the process so, you know at one point 
I could hear my mum and husband talking about 
me but couldn’t voice an answer to them…Now that 
did mean that I was, you know, in a lovely place, and 
I wasn’t feeling any pain at that point but it meant 
that I was almost removed from the labour process. 
(58R)
A number of women in the remifentanil group also 
reflected on how their confused or altered state of mind 
was observed by their birth partners:
I mean my husband said that I was talking about 
the car insurance, I was saying to him, ‘Is the car in-
sured?’…I was having a conversation about the car 
insurance and he was like, this is a weird time to talk 
about the car insurance. (56R)
I was in, kind of in a completely different zone I 
think. My mum and husband were there and said that 
I’d gone from being in incredible pain to just really 
blissed out. (58R)
For both pain relief medications, women likened the 
effects of the analgesia to heavy alcohol consumption:
To be honest I felt incredibly drunk or to the same 
effect. (55P)
It was like being very, very, drunk. (76R)
A further negative impact reported by women with 
respect to both forms of pain relief related to how the 
analgesia had impacted on their memories of labour and 
childbirth:
I must admit within, literally within, I’ve no idea be-
cause I was out of it. […] So then, again I don’t know 
how long I was on it for. […] Or maybe she was cry-
ing. I can’t remember. I can’t remember, sadly. (44R)
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Issues with drug administration
On some occasions, difficulties were experienced due to 
the potential or actual unavailability of remifentanil. For 
example, some women described feeling ‘stressed out’ 
due to concerns about whether the analgesia (drip bag) 
would run out:
The pain relief it was brilliant, really, really good for 
about 3 hours and then the effects started to wear off. 
I don’t know if the contractions were getting worse 
but I was clicking it a lot more than I had originally 
and I was running out of it and I was getting a bit 
stressed out because I was worried that I was going to 
run out. (32R)
In some instances, remifentanil was only reinstated 
after what women felt was a long delay (if at all), leaving 
them unexpectedly without pain relief:
…but to leave someone without, there probably was 
a bit of pain relief in me but that ten minutes was a 
long ten minutes. Yeah, it’s quite traumatising. (63R)
One woman reported that the issue of remifentanil 
running out had contributed to her using epidural 
analgesia:
I ended up going on to have an epidural because 
my medication had finished out and what happened 
was my baby’s heart rate kept dipping in and out. So 
they were a bit concerned and, obviously, I was still in 
pain after that, then I wasn’t fully dilated. So I needed 
something to, to take the edge off, basically, so I did 
go in for an epidural, yes. (7R)
Several women also reported difficulties in opportu-
nities to receive pain relief when the cannula became 
detached:
I’d managed to rip my thingy out, the cannula thing 
so I didn’t have it through the last bit basically be-
cause she said, ‘Oh I can’t get it put back in, you’ll 
just have to go on gas and air for the last bit’. (44R)
For some women, the physiological effects of the 
remifentanil interfered with their ability to use the PCA 
to deliver the pain relief for each contraction:
The other thing was, when I was using the button this 
is, it goes straight to your head, you know, and I was 
so woozy, when my next contraction would come, I 
would forget to press the button. And that contrac-
tion would feel absolutely dire because obviously the 
contraction before it had taken the edge off, and you 
know the midwife had to keep telling me [name] you 
need to press the button, and I was like, oh OK, OK. 
But I was in and out of it if I’m honest, but it was 
good, it was good. (48R)
Whereas for others, as reflected in the quote below, the 
stability of the cannula directly affected their mobility:
When I lifted up my hand it never went in properly, it 
had come up with an error message. So I had to make 
sure my hand was down when I pressed the button, 
which is a bit difficult when you’re in contractions…
No, I told them it wasn’t working but they just told me 
to keep my hand down. (10R)
relections for future choices
Some of the women who received pethidine reported 
that they would opt for this form of pain relief in a future 
birth, even where the analgesia had not been wholly 
effective:
It didn’t get rid of the pain, but I would have it 
again…Yes, I wouldn’t even think about it, I’d just 
have it next time…Obviously I’d go for the gas and 
air again if I could and then if it was like I was told 
I couldn’t have it then I would go for the pethidine. 
(69P)
In converse, others were adamant that they would not 
use pethidine again, that is, ‘I hope I never have to have 
it [pethidine] again’ (55P), and would where possible 
choose an alternative such as remifentanil:
If hell froze over and I got pregnant again, I’d defi-
nitely have, I’d request remifentanil from the get go. 
(25P)
Similar mixed responses were also evident among 
women who received remifentanil. A number of women 
referred to how they would ‘definitely’ use it again:
I definitely felt I needed it so I would definitely have 
it again and I would definitely choose the same form 
of pain relief if it was offered to me again. I felt like 
it really worked for me. It definitely gave me what I 
needed and what I wanted from pain relief so I would 
definitely do the same again. (39R)
And would recommend it to others:
I’ve also said to any other friends…if you are offered 
it [remifentanil], go for it because it’s brilliant. (1R)
Whereas other women, notably all of whom had experi-
enced adverse responses, would either request pethidine 
or make concerted efforts to not use pain relief:
Gas and air, yeah I’d have gas and air again, unless I 
needed it epidural no. I don’t think any of the trial 
drugs, or the drug I had before I wouldn’t have. So 
just gas and air…But me, I don’t think I’d do it again. 
It didn’t agree with me, and yeah I don’t think I’d 
take it myself. (29R)
Impact on infant behaviour and breast feeding
The majority of women (33/49) expressed a prior inten-
tion to breast feed their babies, while 12 women intended 
to formula feed and four had made no plans prior to 
their baby’s birth (see table 1). Within the first hour of 
birth, 47% (14/30) of women in the remifentanil group 
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and 42% (8/19) of women in the pethidine group breast 
fed. By the time of interview (approximately 6 weeks 
postnatal), 47% (14/30) of women in the remifentanil 
group and 26% (5/19) in the pethidine group were 
either exclusively breast feeding or mixed feeding their 
infants. A number of reasons were given for an earlier 
than expected cessation of breast feeding, including 
the level of support received, feeding difficulties such as 
infant tongue- tie and inverted nipples, and health prob-
lems for the mother (eg, lupus, heart condition, mental 
health issues) or the baby (need for antibiotics, cleft 
palate, inadequate weight gain). None of the participants 
felt that the pain relief medication they received influ-
enced their decision to cease breast feeding.
Women in both groups reported feeling exhausted 
immediately following the birth, and how this affected 
their initial interactions with their baby. However, as the 
effects of analgesia, and particularly remifentanil, dissi-
pate after a short period of time, these complaints are 
likely to be attributed to the length and exertions associ-
ated with labour, rather than pain relief analgesia per se:
The first day, obviously, the night that he was born, I 
didn’t [have skin to skin], after he was born I was just 
asleep. When my mum come that evening, that after-
noon, so she was there and my husband was there, 
and that day I was asleep. (11P)
Uncomfortable, tired, drowsy like even the nurses 
had to take over sometimes to feed my son in the 
night because I was that drowsy still and I couldn't, 
I just couldn't take any control, it was a case of I was 
falling asleep with him on me and stuff like that be-
cause I was just so tired. (17R)
Other women felt so weak that they needed help from 
their birth partners to hold their babies:
So he was born, they were saying, give him milk, they 
put him on to my breast and I was giving him the milk 
but my arms didn’t have that much strength to hold 
him, my husband had to help me out. (11P)
One woman who had progressed to epidural analgesia 
reflected on her increasing frustration at not being able 
to breast feed her baby:
I was so exhausted. I couldn't really move because of 
my epidural and I was getting really tired and a bit 
emotional and everything so it wasn't, breastfeeding 
wasn't working basically. (44R)
DISCuSSIOn
This study aimed to explore women’s experiences of 
remifentanil and pethidine use for pain relief during 
labour and infant feeding behaviours up to approximately 
6 weeks post partum. The findings revealed that while 
many women had actively researched pain relief options 
prior to their birth and had either formulated birth plans 
or had decided to adopt a more flexible approach to 
pain management, most were unfamiliar with the opioid 
remifentanil until they were informed about the trial. The 
majority of women who had used remifentanil felt that it 
had provided effective pain relief. This was not the case 
with women in the pethidine group, who had more mixed 
views, with many reporting that pethidine was completely 
ineffective at relieving their pain. This was consistent 
with the findings of the RESPITE trial, which showed 
that women’s views of their pain relief effectiveness 
and average pain scores were significantly better in the 
remifentanil arm.10 These insights also support a recent 
study by Fleet and colleagues,9 who compared women’s 
use of pethidine and fentanyl (delivered on an intranasal 
or subcutaneous basis). Fleet and colleagues’ study found 
that women who received fentanyl provided more posi-
tive, and less negative responses compared to those who 
received pethidine.9 However, it is important to note that 
while effective pain management has become an essen-
tial component of the care plan for expectant mothers, 
women’s perceptions of pain are affected by physiological 
and/or psychological issues (eg, fear, anxiety),15 as well as 
the nature of the woman- provider relationship.16
Women using either form of pain relief reported expe-
riencing a number of side effects, although these tended 
to differ according to the analgesia used. Women using 
pethidine frequently reported feeling nauseated, consis-
tent with the findings of Fleet and colleagues,9 whereas 
this was only reported by one woman who had used 
remifentanil. Women in both groups reported that the 
opioid made them feel drowsy, although this seemed to 
be less pronounced in the remifentanil group. These 
insights support the RESPITE trial findings10 and the 
work of others such as Volikas and Male17 with regard to 
the sedative effects of opioid- based forms of pain relief.
A number of negative comments arose relating to the 
nature of remifentanil administration. Women in the 
remifentanil group described how the PCA restricted 
their movements, and for a small number this resulted in 
pain (as a result of technically flawed intravenous cannu-
lation) and frustration. Others experienced anxiety or 
difficulties due to the potential or actual unavailability 
of remifentanil. Women reported feeling anxious about 
whether the analgesia (drip bag) would run out, and on 
occasions when it did, they experienced significant delay 
in its reinstatement. On some occasions, women consid-
ered that this may have contributed to their progression 
to epidural analgesia. Other qualitative researches have 
also highlighted how opioids administered too late, or 
which wore off too early, created fear and anxiety.9 18 It 
is important to note that these technical difficulties are 
not inevitable components of PCA and are amenable to 
resolution.
One of the key advantages of remifentanil highlighted 
by women was how it provided pain relief and main-
tained their ability to stay focused during the birth. 
Several women referred to how PCA enabled them to 
use pain relief selectively, as required. In this sense, they 
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saw remifentanil as an opportunity to stay in control and 
actively manage their own labour (not just the pain), 
helping them to find reference points for their own 
understanding of their progression and tolerance to pain. 
The ability to maintain focus was probably related to the 
short- acting effect of remifentanil which enhanced their 
sense of control. The association between the use of phar-
macological pain relief and increased sense of control has 
also been reported by others.9 12 19 20
A further notable finding, as reflected by others,9 21 
relates to women experiencing a cognitive impact from 
the analgesics. Some women reported feeling discon-
nected from their labour and unable to focus or process 
external stimuli. Similar findings were reported in a 
study by Whitburn and colleagues to explore women’s 
experiences of labour pain. They found that an inability 
to retain focus during labour was associated with self- 
judgement and negative perspectives of pain.22 Some 
women felt that remifentanil impacted on their memory 
and affected their ability to recall their baby’s birth. While 
this was not found in Fleet and colleagues’ study,9 these 
differences may be related to additional factors such as 
levels of fear, and dosage of the medication, or the fact 
that more women in our study received remifentanil than 
pethidine.
In relation to infant feeding, the main trial found no 
difference in breast feeding within an hour of birth in the 
two trial arms10; with a similar pattern noted among those 
in this sub- study. Forty- seven per cent of women in the 
remifentanil and 42% of women in the pethidine arms 
initiated breast feeding within the first hour after birth. At 
around 6 weeks postnatal, the rates of ‘any’ breast feeding 
were 26% for women who used pethidine compared to 
46% of women in the remifentanil group. While these 
variations may be attributable to the level of postnatal 
support for breast feeding across the different areas, the 
findings do support those by Fleet and colleagues23 in that 
women who used remifentanil had fewer breastfeeding 
difficulties. These differences may relate to the differen-
tial effects of analgesia on infant behaviours which may 
impact on establishment of sustained breast feeding.24 
However, as there are many biopsychosocial factors that 
can influence the mother’s infant feeding decisions, 
further research is needed.
To our knowledge, this is the first study to explore the 
experiences of women using intravenous remifentanil 
PCA for pain relief in labour in depth, by formal, qual-
itative methodology. The study comprised a qualitative 
sub- study to a multicentre randomised controlled trial 
(RCT) that compared intravenous remifentanil PCA with 
intramuscular pethidine for pain relief in labour. The 
strengths of this study are that to date, there is minimal 
qualitative research to understand women’s experiences 
of opioid use during labour, and the substantial number 
of interviews conducted in multiple sites across England. 
The limitations relate to the relatively fewer women 
recruited who were randomised to pethidine, and it may 
be that women who held stronger views towards the use 
of analgesia (positive or negative) took part in the study. 
The high attrition rates for the study highlight challenges 
intrinsic to early recruitment into postpartum studies. For 
example, women may not have been fully cognisant of 
what they were agreeing to, and difficulties are encoun-
tered in organising data collection when participants 
are dealing with the demands of a new baby. It is also 
important to reflect that 41 (84%) of our sample received 
Entonox prior to randomisation and in combination with 
pethidine, and 11 (22%) progressed to epidural anal-
gesia, which may have influenced their experiences.
COnCluSIOnS
Qualitative insights from a follow- up sub- study to an open- 
label trial that compared intravenous remifentanil PCA 
with intramuscular pethidine injection highlighted valu-
able differences. Overall, more women found remifent-
anil to be an effective pain relief compared to the mixed 
views of women who received pethidine. All women 
experienced side effects although these differed between 
groups, with a number of the difficulties associated with 
remifentanil related to drug administration rather than 
impact of the analgesia. While negative experiences of 
remifentanil included restricted movements due to drug 
administration, a key advantage of this form of pain relief 
was how its short- lasting nature enabled women to remain 
focused during the birth. Overall, while there was little 
difference in breastfeeding initiation rates, there was an 
indication that women who received remifentanil were 
more likely to continue breast feeding. While these varia-
tions may be attributable to different numbers of women 
included from the trial groups and the level of postnatal 
support for breast feeding across the different geograph-
ical areas, it may be that women who used remifentanil 
had fewer breastfeeding difficulties.
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